Founder & Medical Director
Dr Ramia de Cap provides clinical leadership at Pathology Nucleus, overseeing project design, specialist selection, delivery and quality assurance, so every client has one accountable consultant from the first conversation to the final report.
He is a US board-certified pathologist specialising in anatomic pathology and haematopathology, and is GMC-registered. He completed his specialist training at Harvard-affiliated hospitals in Boston, including Beth Israel Deaconess Medical Center, and has been an NHS consultant pathologist in London for the past five years.
Alongside his clinical practice, he has developed FlowSight and HaemPath, diagnostic software in routine NHS use, and has led projects in digital pathology, structured clinical data and AI evaluation.
Selected peer-reviewed publications
Dr Ramia de Cap has authored or co-authored 14 PubMed-indexed publications, spanning haematopathology, dermatopathology and pathology methodology. View all publications on PubMed.
- Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.
- Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.
- Investigation of NPM1 mutation frequency in cutaneous blastic plasmacytoid dendritic cell neoplasms.
- Limitations of multivariate survival analysis.